ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,197Medicare Part D Prescriptions Filled, Including Refills

Rank: 245 out of 1206

$497K Total Retail Price of All Prescriptions

Rank: 169 out of 1206

567 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Iowa
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 567 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

12% of this provider’s 567 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 7,704 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $46 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Iowa
SIMVASTATIN 494 444 1 1
LISINOPRIL 369 314 2 4
OMEPRAZOLE 309 268 3 3
LEVOTHYROXINE SODIUM 303 257 4 2
ATENOLOL 279 251 5 14
CITALOPRAM HBR 253 217 6 16
FUROSEMIDE 208 177 7 5
ZOLPIDEM TARTRATE 190 158 8 25
HYDROCODONE-ACETAMINOPHEN 160 109 S3 9 7
METFORMIN HCL 143 96 10 10
ATORVASTATIN CALCIUM 139 134 11 13
AMLODIPINE BESYLATE 139 134 11 6
WARFARIN SODIUM 136 113 13 8
ROPINIROLE HCL 126 108 14 77
DONEPEZIL HCL 121 121 15 29
METOPROLOL TARTRATE 117 117 16 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 117 102 16 27
PRAVASTATIN SODIUM 116 89 18 21
ALLOPURINOL 107 86 19 24
ALENDRONATE SODIUM 106 88 20 19
HYDROCHLOROTHIAZIDE 103 92 21 11
LOSARTAN POTASSIUM 99 94 22 20
GABAPENTIN 92 66 23 18
MELOXICAM 92 61 23 35
NAMENDA 87 87 25 36
TRAMADOL HCL 85 55 26 17
POTASSIUM CHLORIDE 82 73 27 12
METOPROLOL SUCCINATE 78 63 28 15
ESCITALOPRAM OXALATE 76 72 29 86
GEMFIBROZIL 72 62 30 71
POLYETHYLENE GLYCOL 3350 72 67 30 31
SERTRALINE HCL 72 62 30 22
LOVASTATIN 71 66 33 44
AZITHROMYCIN 68 57 34 46
TERAZOSIN HCL 63 57 35 81
ADVAIR DISKUS 62 60 36 55
CLOPIDOGREL 61 59 37 48
RANITIDINE HCL 60 45 38 23
PREDNISONE 59 50 39 28
FLUOXETINE HCL 58 47 40 52
VENLAFAXINE HCL ER 57 57 41 89
SULFAMETHOXAZOLE-TRIMETHOPRIM 56 45 42 82
CYMBALTA 55 36 43 63
ZETIA 53 50 44 73
AMITRIPTYLINE HCL 52 45 R 45 59
PROAIR HFA 52 38 45 49
GLYBURIDE 52 35 R 45 69
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 25, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.